Cellular and Humoral Systemic and Mucosal Immune Responses Stimulated by an Oral Polybacterial Immunomodulator in Patients with Chronic Urinary Tract Infections

Abstract

An oral polybacterial immunomodulator Urostim (U), composed of killed cells and their lysates from E. coli expressing type 1 and P-pili, E. coli Rc mutant, P. mirabilis, K. pneumoniae and E. faecalis was created for immunoprophylaxis and immunotherapy of urinary tract infections (UTIs). In experimental animal models, the stimulating effect ofU on lymphocyte functional activity, macrophage phagocytosis and antibody producing cells, was established. In this study the immuno-modulating effects of U on the proliferating capacity and ultrastructural morphologic changes of lymphocytes, cytokine production and specific systemic humoral and mucosal immune responses in patients with UTIs have been evaluated. Patients enrolled in the study, received orally 50 mg U daily for a period ofthree months. On days 0, 30 and 90 a quantitative analysis was performed on lymphoproliferative responses to polyclonal mitogens, IL-2 and the specific antigen U, the production of specific serum and saliva IgA, IgM and IgG antibodies to all components of U and the concentration of pro-inflammatory cytokines. There was significant improvement of non-specific and specific lymphoproliferative responses on days 30 and 90 after the onset oftreatment with U, confirmed by electronmicroscopic studies. The highest concentrations of serum proinflammatory cytokines TNF-a, IL-lj3, and IL-6 were registered at baseline followed by a decrease until the end ofthe observation period. This finding correlates with the gradual decrease of immune activation as measured by the spontaneous lymphocyte proliferation. Data from the production of specific antibacterial antibodies in serum and saliva show two types of reactions. The first type was registered in patients with low pre-treatment levels in whom the concentration of specific antibodies increased on days 30 and 90. The second type of reaction was observed in patients with high pre-treatment levels,which dropped on day 30 and were usually followed by an increase at the end of the study. These results provide evidence for the immuno-modulating effect of U. Our data show that the oral administration of the polybacterial immunomodulator Urostim stimulates adequate cellular and humoral systemic and mucosal immune responses in patients with chronic UTIs.In recent years mucosal vaccines have produced great scientific and practical results. More than three decades of research in experimental models have shown promising results in stimulating mucosal immune responses (1). Mucosa of the urinary tract is the port of entry for different bacterial species (Escherichia, Proteus, Klebsiella, Citrobacter, Pseudomonas etc.), the causative agents of chronic and recurrent infections (2-3). Urinary tract infections (UTIs) are among the most common bacterial infections in humans and are a serious problem in medical practice (4-6). The most frequent etiologic agent ofUTIs is Escherichia coli, especially the one possessing type 1 pili, acting as adhesions and

Polybacterial immunomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections

“…It should be pointed out that Respivax treatment did not change the level of the proliferation inducing cytokine IL-2, in consensus with the results obtained for other similar preparations, Urostim and Dentavax [22,66]. Therefore, Respivax treatment does not induce a spontaneous proliferative response, which is an important requirement for any immunomodulating treatment.…”

“…The polybacterial immunomodulator Respivax (BB-NCIPD Ltd.) has a well documented beneficial clinical effect in chronic non-specific respiratory conditions [1][2][3][4][5]22]. The purpose of the present study was to investigate for the first time its ex vivo effects on the inductive function of innate immunity in man.…”

Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator “Dentavax”

“…10 and 11). Our previous publications [57,58] provide evidence that another oral polybacterial immunomodulator Urostim (U) stimulates cellular and humoral immune responses in patients suffering from chronic recurrent urinary tract infections. During the period of treatment with U and one year later no relapses of infection were observed [58].…”

Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic Escherichia coli ΔtolR IHE3034 Mutant

“…Different approaches have been undertaken in this direction (6), but none of them have so far led to a product sufficiently satisfactory for human use. A variety of whole-cell vaccine formulations, administered via vaginal or oral routes, have been assessed in animal models and human clinical trials in Europe (7)(8)(9)(10)(11)(12)(13)(14)(15). These vaccines hold some promise but require further evaluation, particularly in consideration of the fact that whole cell-based vaccines are likely to elicit undesired immune responses against antigens shared with commensal E. coli strains.…”